GlassScriptPhysician profile
Yelena Iglanova
NPI 1033289194
$6,891.73
in general payments reported to CMS, 2019-2025
27 companies · $2,663 in 2025
The $2,663 reported for 2025 was more than what 97% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $2,392 · 2024: $1,624 · 2025: $2,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,638 · Education: $40.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,638.26 |
| Education | $40.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $794.91 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $608.33 | 2024-2025 | Cobenfy |
| Corium, LLC | $573.14 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $563.72 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $525.78 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $507.88 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $490.01 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $357.66 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $292.29 | 2023-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $276.68 | 2023-2024 | Quviviq |
| Bausch Health US, LLC | $255.47 | 2023-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $242.82 | 2023-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $242.39 | 2023-2025 | Qelbree, Qelbree |
| Inari Medical, INC. | $212.68 | 2022 | |
| Vanda Pharmaceuticals INC. | $197.64 | 2024-2025 | Fanapt, Hetlioz |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $182.90 | 2023-2024 | Auvelity, Sunosi |
| Indivior INC. | $109.64 | 2024-2025 | Sublocade |
| Almatica Pharma LLC | $91.33 | 2024-2025 | Loreev Xr |
| Tris Pharma INC | $70.68 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $61.74 | 2023 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $57.12 | 2023-2025 | Relexxii |
| Biogen, INC. | $52.01 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $33.43 | 2023 | Methylphenidate Hydrochloride |
| Takeda Pharmaceuticals U.S.A., INC. | $32.81 | 2023 | Trintellix |
| Collegium Pharmaceutical, INC. | $23.88 | 2025 | Jornay Pm |
| Luye Pharma (USA) LTD. | $18.99 | 2025 | Erzofri Extended-Release |
| Neos Therapeutics, LP | $15.80 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelena Iglanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.